Urokinase receptor forms in serum from non-small cell lung cancer patients: Relation to prognosis
Authors:
- Ib Jarle ChristensenICIb Jarle Christensen
- Gunilla Høyer-HansenGHGunilla Høyer-Hansen
- Keld DanøKDKeld Danø
- Helle PappotHPHelle Pappot
- Hendrik DienemannHDHendrik Dienemann
- Thomas MuleyTMThomas Muley
- 1 December 2011
- journal article
- Published by Elsevier in Lung Cancer
- Vol. 74 (3) , 510-515
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- Prognostic significance of urokinase plasminogen activator receptor and its cleaved forms in blood from patients with non‐small cell lung cancerAPMIS, 2009
- Tumor volume and tumor marker index based on CYFRA 21-1 and CEA are strong prognostic factors in operated early stage NSCLCLung Cancer, 2008
- The Impact of Additional Prognostic Factors on Survival and their Relationship with the Anatomical Extent of Disease Expressed by the 6th Edition of the TNM Classification of Malignant Tumors and the Proposals for the 7th EditionJournal of Thoracic Oncology, 2008
- Association of the Circulating Levels of the Urokinase System of Plasminogen Activation With the Presence of Prostate Cancer and Invasion, Progression, and MetastasisJournal of Clinical Oncology, 2007
- Cancer Statistics, 2007CA: A Cancer Journal for Clinicians, 2007
- Enhanced Discrimination of Benign from Malignant Prostatic Disease by Selective Measurements of Cleaved Forms of Urokinase Receptor in SerumClinical Chemistry, 2006
- Prognostic impact of liberated domain I of the urokinase plasminogen activator receptor in squamous cell lung cancer tissueLung Cancer, 2005
- Plasminogen activation and cancerThrombosis and Haemostasis, 2005
- Specific Immunoassays for Detection of Intact and Cleaved Forms of the Urokinase ReceptorClinical Chemistry, 2004
- Cell‐Surface Acceleration of Urokinase‐Catalyzed Receptor CleavageEuropean Journal of Biochemistry, 1997